2025-05-28-Jefferies-Savara_Inc.（SVRA）_初步先例分析表明CMC问题可能很快得到解决_14页_484kb

Savara Inc. (SVRA) Equity Research Summary

Executive Overview

• Jefferies maintains a "BUY" rating on SVRA, with a price target of $8.50, up from $1.94, implying a 338% upside. The report highlights strong confidence in eventual FDA approval of inhaled GM-CSF (Molbreevi) for autoimmune pulmonary alveolar proteinosis (aPAP), based on positive Phase III data, lack of approved therapies, and a potential resolution of Chemistry, Manufacturing, and Controls (CMC) issues.

CMC Challenges and Resolution

• The FDA issued a Refuse-to-File (RTF) letter due to CMC concerns. Historical precedents (e.g., NVO's Ozempic, BMY's Abecma) show RTFs typically resolved in 2-3 months, with subsequent approvals. Fujifilm has completed upstream Process Performance Qualification and is undergoing downstream processes to enable a Q4 2025 resubmission, potentially avoiding delays.

Investment Thesis

• Outcome: 90%+ probability of FDA approval, supporting $400M+ peak sales justified by high unmet need in aPAP. Key catalysts include timely supplier integration (via Fujifilm or alternative suppliers) and streamlined regulatory review.
• Financial Projections: NPV analysis suggests strong shareholder value due to rapid approval. Downside scenarios consider lower sales or approval delays, but upside potential is emphasized with a base case of $8.50 and upside scenario to $15.00.

Timeline and Catalysts

• Key Events:
  • Q4 2025: BLA resubmission following CMC fixes.
  • YE 2025: Potential submissions to the EMA.
  • YE 2026: EU/ ex-U.S. approvals projected.
• Funding and Partnerships: Fujifilm's tech transfer completion could expedite resubmission; supplier dynamics may resolve ambiguities.

Risks and Considerations

• CMC and Manufacturing: RTF concerns need swift resolution; reliance on suppliers like Fujifilm adds buffer, but oversight issues could cause delays.
• Regulatory and Commercial: Delays or rejection despite precedents pose risks, and competition or market access challenges may limit revenue potential.
• Short-Term Focus: Current financials show losses, but expected growth from Molbreevi drives optimism. Jefferies notes historical precedents support rapid resolution.